MX2023004089A - Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12. - Google Patents

Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12.

Info

Publication number
MX2023004089A
MX2023004089A MX2023004089A MX2023004089A MX2023004089A MX 2023004089 A MX2023004089 A MX 2023004089A MX 2023004089 A MX2023004089 A MX 2023004089A MX 2023004089 A MX2023004089 A MX 2023004089A MX 2023004089 A MX2023004089 A MX 2023004089A
Authority
MX
Mexico
Prior art keywords
adc
bind
methods
proteins
drug conjugates
Prior art date
Application number
MX2023004089A
Other languages
English (en)
Spanish (es)
Inventor
Elaina Marie Gartner
Eric John Chown
Tina Kim-Hafken
Dana Ann Kennedy
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of MX2023004089A publication Critical patent/MX2023004089A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
MX2023004089A 2020-10-11 2021-10-08 Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12. MX2023004089A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063090272P 2020-10-11 2020-10-11
US202163148038P 2021-02-10 2021-02-10
US202163193493P 2021-05-26 2021-05-26
PCT/US2021/054084 WO2022076767A1 (en) 2020-10-11 2021-10-08 Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins

Publications (1)

Publication Number Publication Date
MX2023004089A true MX2023004089A (es) 2023-06-28

Family

ID=81125466

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004089A MX2023004089A (es) 2020-10-11 2021-10-08 Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12.

Country Status (10)

Country Link
US (1) US20230364254A1 (cg-RX-API-DMAC7.html)
EP (1) EP4225379A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023545432A (cg-RX-API-DMAC7.html)
KR (1) KR20230106607A (cg-RX-API-DMAC7.html)
AU (1) AU2021356542A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198359A1 (cg-RX-API-DMAC7.html)
IL (1) IL302006A (cg-RX-API-DMAC7.html)
MX (1) MX2023004089A (cg-RX-API-DMAC7.html)
TW (1) TW202228788A (cg-RX-API-DMAC7.html)
WO (1) WO2022076767A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202191201A1 (ru) 2018-12-03 2022-01-26 Эдженсис, Инк. Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения
CN117982672A (zh) * 2022-07-14 2024-05-07 百奥泰生物制药股份有限公司 抗Nectin-4抗体药物偶联物及应用
WO2024012536A1 (zh) * 2022-07-14 2024-01-18 百奥泰生物制药股份有限公司 抗Nectin-4抗体、其抗体药物偶联物及应用
CN118871132A (zh) * 2023-02-27 2024-10-29 石药集团巨石生物制药有限公司 重组人源化抗Nectin-4单抗-MMAE偶联药物的药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2874306T3 (es) * 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
CA3111401A1 (en) * 2018-09-19 2020-03-26 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
EA202191201A1 (ru) * 2018-12-03 2022-01-26 Эдженсис, Инк. Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения
AU2020241963B2 (en) * 2019-03-17 2026-07-02 Vasgene Therapeutics Inc Treatment of cancers using sEphB4-HSA fusion proteins
EP4013795A4 (en) * 2019-08-13 2023-11-15 Agensys, Inc. TREATMENT OF CANCERS WITH ANTIBODY-DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
JP2023542879A (ja) * 2020-09-17 2023-10-12 アジェンシス,インコーポレイテッド 191p4d12タンパク質に結合する抗体薬物複合体(adc)を用いたがんの治療方法

Also Published As

Publication number Publication date
TW202228788A (zh) 2022-08-01
KR20230106607A (ko) 2023-07-13
US20230364254A1 (en) 2023-11-16
JP2023545432A (ja) 2023-10-30
AU2021356542A9 (en) 2024-05-23
AU2021356542A1 (en) 2023-05-25
IL302006A (en) 2023-06-01
EP4225379A4 (en) 2025-11-19
EP4225379A1 (en) 2023-08-16
CA3198359A1 (en) 2022-04-14
WO2022076767A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
PH12022550318A1 (en) Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
PH12022551098A1 (en) Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
MX2024011292A (es) Conjugados de camptotecina.
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
TW201713360A (en) Methods of treating cancer using compositions of antibodies and carrier proteins
CY1121023T1 (el) Συζευγματα αντισωματος φαρμακου (adc) τα οποια δεσμευονται σε 191p4d12 πρωτεϊνες
CY1123525T1 (el) Μορια δεσμευσης ειδικα για asct2 και χρησεις αυτων
DOP2012000052A (es) Proteínas terapéuticas de unión a dll4
CO6612264A2 (es) Proteinas terapeuticas de la union a dll 4
EA201391449A1 (ru) Антитела против пептидов цитозоля
EA202090387A1 (ru) Белки, связывающие nkg2d, cd16 и flt3
CY1123743T1 (el) Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου
EA201600190A1 (ru) Анти-prlr антитела и их применение
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
PH12023550745A1 (en) Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
MX2025004353A (es) Construcciones de proteinas de union a lrrc15 y usos de estas
WO2023133388A3 (en) Methods for treating muscle invasive urothelial cancer or muscle invasive bladder cancer with antibody drug conjugates (adc) that bind to 191p4d12 proteins
AU2021344976A9 (en) Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
MX2022016232A (es) Marcadores para uso en metodos para tratar canceres con conjugados de anticuerpo y farmaco (adc).
WO2022183112A3 (en) Compositions and methods comprising antibodies that bind to covalent peptide conjugates
MX2024001834A (es) Metodos para tratar el cancer de vejiga no muscular invasivo (nmibc) con conjugados de anticuerpos y farmacos (adc) que se unen a las proteinas 191p4d12.
MX2025000819A (es) Metodos para el tratamiento de pacientes con cancer urotelial localmente avanzado o metastasico con conjugados de anticuerpo-farmaco (adc) que se unen a las proteinas 191p4d12 en combinacion con pembrolizumab
MX2025004438A (es) Novedosos conjugados-anticuerpo-droga con novedosos anticuerpos napi2b, metodos terapeuticos y usos de los mismos
MX2024001363A (es) Metodos para el tratamiento de la leucemia mieloide aguda con los anticuerpos anti-ilt3.
HK40095645A (en) Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins